31 August 2020 in Annals of Hepato-Biliary-Pancreatic Surgery
Ashley Rosenberg, Katarzyna Trebska-McGowan, Trevor Reichman, Amit Sharma, Adrian Cotterell, Brian Strife, Aamir A. Khan, Vinay Kumaran, David A. Bruno, Marlon F. Levy, and Chandra Shekhar Bhati. Ann Hepatobiliary Pancreat Surg 2020;24:333-8. https://doi.org/10.14701/ahbps.2020.24.3.333
8 January 2025 in Surgical Endoscopy
Background: Robotic living donor hepatectomy offers potential advantages but has been limited to high-volume centers, primarily in Asia and the Middle East. We report our experience establishing a robotic living donor right hepatectomy program in a U.S. center with low LDLT volume and no prior laparoscopic donor hepatectomy experience and analyze early outcomes. Methods: This retrospective cohort study analyzed 37 living donor right hepatectomies (13 robotic [including one open conversion], 24 open) performed between June 2022 and February 2024. Results: The robotic group had longer operative times (median [range], 451 [374–568] minutes vs 368 [276–421] minutes; P < 0.001) but less blood loss (median [range], 200 [50–700] mL vs 900 [300–2500] mL; P < 0.001). One case required unplanned open conversion due to gas embolism. Two hematomas/bleeding (Clavien–Dindo grade IIIB) occurred in the robotic group, but no biliary complications. Comprehensive Complication Index, liver function tests, and hospital stays were similar between the two groups, with no 90-day graft failure/mortality. Conclusion: With extensive surgical experience in both open donor hepatectomy and robotic surgery, along with meticulous preparation as a team, U.S. centers with lower LDLT volume and no laparoscopic experience can safely implement robotic living donor right hepatectomy, achieving comparable short-term outcomes to the open approach. Further research on long-term outcomes and donor quality of life is necessary.
15 February 2024 in American Journal of Transplantation
Islets experience enormous stress during the isolation process, leading to suboptimal endocrine function after total pancreatectomy with islet autotransplantation (TPIAT). Our investigation focused on inducing isolation stress in islets ex vivo, where proinflammatory cytokines and hypoxia prompted the release of stress exosomes (exoS) sized between 50-200nm. Mass spectrometry analysis revealed three distinct subgroups of immunogenic proteins within these exoS: damage-associated molecular patterns (DAMPs), chaperones, and autoantigens. The involvement of endosomal sorting complex required for transport (ESCRT) proteins - RAB7A, RABGGTA, VPS45, VPS26B, and the tetraspanins CD9 and CD63 - in exoS biogenesis was confirmed through immuno-blotting. Next, we isolated similar exoS from the islet infusion bags of TPIAT recipients (N=20). The exosomes from infusion bags exhibited higher DAMP (HSPA1B, and histone H2B) levels, particularly in the insulin-dependent (ID) TPIAT group. Additionally, elevated DAMP protein levels in islet infusion bag exosomes correlated with increased insulin requirements (p=0.010) and higher HbA1c levels one year post-transplant. A deeper exploration into exoS functionality revealed their potential to activate monocytes via the toll-like receptor TLR3/7: DAMP axis. This stimulation resulted in the induction of inflammatory phenotypes marked by increased levels of CD68, CD80, iNOS, and COX-2. This activation mechanism may impact the successful engraftment of transplanted islets.
30 January 2026 in Clinical Transplantation
Normothermic regional perfusion (NRP) has emerged as a pivotal strategy in controlled donation after circulatory death (cDCD) liver transplantation, mitigating ischemia‐reperfusion injury and improving graft outcomes. Compared to super rapid recovery (SRR), NRP significantly reduces rates of early allograft dysfunction, primary nonfunction, and biliary non‐anastomotic stricture (NAS), with biliary complications reported in 5%–16% and NAS as low as 0%–2%. Outcomes from cDCD‐NRP grafts are increasingly comparable to those of donation after brain death (DBD). Viability assessment during NRP remains variably defined across centers. Nonetheless, stable pump flow, stable or declining lactate levels, controlled transaminase levels, and favorable macroscopic appearance are commonly used parameters. Histological thresholds may guide graft acceptance but are not universally applied. Sequential use of ex situ machine perfusion following NRP offers additional benefits in marginal or prolonged ischemia settings. NRP implementation has improved liver utilization rates from 34% to 63% in the United Kingdom and from 39% to 71% in the United States. This review highlights NRP as a transformative platform that reshapes viability standards, expanding transplant access, and supports sustained growth in liver transplantation.
27 September 2023 in Clinical Transplantation
Background: Post‐COVID‐19 cholangiopathy is an emerging cholestatic liver disease observed in patients recovering from severe COVID‐19 infection. Its prognosis is poor, necessitating liver transplantation in some cases. This study aimed to investigate the outcomes of liver transplantation for post‐COVID‐19 cholangiopathy.Methods: Seven patients who underwent liver transplantation for post‐COVID‐19 cholangiopathy at three institutions between 2020 and 2022 were included in this retrospective multi‐center case series.Results: At the time of initial COVID‐19 infection, all patients developed acute respiratory distress syndrome, and six patients (86%) required ICU admission. Median time intervals from the initial COVID‐19 diagnosis to the diagnosis of post‐COVID‐19 cholangiopathy and liver transplantation were 4 and 12 months, respectively. Four patients underwent living donor liver transplantation, and three patients underwent deceased donor liver transplantation. The median MELD score was 22 (range, 10–38). No significant intraoperative complications were observed. The median ICU and hospital stays were 2.5 and 12.5 days, respectively. One patient died due to respiratory failure 5 months after liver transplantation. Currently, the patient and graft survival rate is 86% at a median follow‐up of 11 months.Conclusions: Liver transplantation is a viable option for patients with post‐COVID‐19 cholangiopathy with acceptable outcome. Timely identification of this disease and appropriate management, including evaluation for liver transplantation, are essential.
24 March 2022 in Transplantation